Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Reports & Briefings
Brazil is one of many governments working to strike a balance between public and private interests in determining how medical innovation is conducted and incentivised – and how medical products and technologies can be made accessible for the benefit of public health. At this point, several bills and recommendations have been tabled in the Brazilian Congress.
Last updated 8 September 2015
An estimated five million people around the world are bitten by venomous snakes every year. Snakebite kills as many as 100,000 people and leads to disability and disfiguration for some 400,000 victims globally each year. Most of the victims come from remote, rural areas. With no health facilities nearby, and unable to afford expensive treatment, many either forego treatment completely or turn to traditional healers.
Last updated 7 September 2015
Snakebite is a neglected health issue which kills anywhere from 20,000 to 95,000 people globally each year. In sub-Saharan Africa, it is estimated that between 4,000 and 30,000 people die per year. In 2010, Sanofi made the internal decision to stop production of Fav-Afrique, a highly effective and affordable antivenom. In January 2014, the last batch of Fav-Afrique was produced and very quickly sold out, leading to a shortage. The expiry date – or the end of the shelf life – for the last batch of Fav-Afrique produced is June 2016.
Last updated 7 September 2015
The global response to HIV/AIDS is neglecting crucial but underfunded resources necessary to keeping millions on lifelong, daily care, especially in Sub-Saharan Africa that has the double challenge of addressing high HIV and TB burdens with the lowest number of health care workers, the international humanitarian organization Médecins Sans Frontières/Doctors Without Borders (MSF) said ahead of the IAS conference on HIV pathogenesis, treatment and prevention.
Last updated 20 July 2015
A product guide for point-of-care CD4 and laboratory-based and point-of-care virological HIV and HCV tests This product guide is for policymakers, treatment providers and advocates interested in learning more about laboratory-based and point-of-care virological HIV and hepatitis C (HCV), and point-of-care CD4, diagnostic and monitoring tests. DOWNLOAD THE REPORT
Last updated 15 July 2015
In this issue brief, we review trends in generic competition and intellectual property (IP) licensing for key antiretroviral drugs. We then outline seven momentous decisions to be made in 2015 that will largely determine whether ART will be affordable, available and robust for the next 15 years of treatment scale-up to all people living with HIV.
The Trans-Pacific Partnership (TPP) trade deal is currently being negotiated between the US and eleven other Pacific Rim nations: Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam. The agreement is slated to further expand its membership, potentially to all 21 Asia Pacific APEC nations.
Last updated 14 July 2015
Médecins Sans Frontières (MSF) would like to share comments and recommendations concerning the Global Fund to Fight AIDS, Tuberculosis and Malaria’s Market Shaping Strategy, Procurement for Impact (P4i) programme and E-Marketplace.
Last updated 9 July 2015
MSF is in the process of starting to treat people who are living with hepatitis C virus (HCV) in at least nine countries, and therefore is in need of affordable access to direct acting antiviral (DAA) treatments, including those marketed by Gilead Sciences (Gilead) and Bristol-Myers Squibb (BMS).
Last updated 18 May 2015
The international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) began introducing hepatitis C virus (HCV) treatment to several patients in India in 2013. MSF is in the process of scaling up treatment for HCV in at least eight additional countries, using direct-acting antiviral (DAA) medicines that have recently come to market with the potential to revolutionise treatment for people living with HCV.
Last updated 21 April 2015